Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PharmaMar, Megapharm Partner for Multiple Myeloma | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PharmaMar, Megapharm Partner for Multiple Myeloma

The commercialization and distribution license agreement is for Aplidin (plitidepsin)

By: Betsy Louda

, Contract Pharma

PharmaMar is entering a commercialization and distribution license agreement with Megapharm for the marine-derived anticancer drug Aplidin (plitidepsin) in Israel and the territory known as the Palestinian Authority.

 

The drug is for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. 

 

Under the agreement, Megapharm will register Aplidin on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use. 

 

PharmaMar announced in March 2016 that plitidepsin had positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma.

 

Miron Drucker, chief executive officer of Megapharm, said, “The agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israel and the territory known as the Palestinian Authority.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics